The Bradford Era

Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3 tri...

INDIANAPOLIS , April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025 ...

New tools to connect with independent in-person and telehealth providers specializing in Alzheimer's disease are designed to increase capacity and red...

INDIANAPOLIS , Feb. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on Ma...

The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Me...

Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in Ame...

New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program 2.5 mg and 5 mg vial prices red...

INDIANAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45 th Annual Health Care Conference on M...

More than 90% ofOmvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of pa...